{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}],"title":"Cycle 1 dose 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50"}]}],"title":"Cycle 1 dose 2 thru Cycle 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Recommended dose determined by number of DLTs \\[non-hematologic toxicity grade 3 or greater (excluding not life-threatening transient liver function or transient electrolyte abnormalities, fatigue, or diarrhea resolving within 4 days), some grade 2 toxicity (i.e. irreversible renal, chronic pulmonary, neurologic, or cardiac toxicity), hematologic toxicity of grade 4 thrombocytopenia/neutropenia persisting for 7 days or greater, or inability to continue cycle 2 by 7 weeks for reasons other than disease progression\\] and consideration of number of patients with severe tumor lysis requiring hemodialysis with dose 1.","groups":[{"description":"Flavopiridol was escalated to 30mg/m2 bolus followed by 50 mg/m2 4 hour beginning Dose Level 2 Cycle 1 for 6 Cycles.","id":"OG000","title":"Dose Level 4"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 6 weeks","title":"Recommended Dose Level of Flavopiridol","type":"PRIMARY","unitOfMeasure":"mg/m^2"}